US FDA classifies recall of Abiomed's blood pumps as most serious-March 2024-www.financetom.com

US FDA classifies recall of Abiomed's blood pumps as most serious

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA classifies recall of Abiomed's blood pumps as most serious

Mar 21, 2024 8:13 AM

March 21 (Reuters) - The U.S. health regulator on

Thursday classified the recall of some Impella Left Sided Blood

Pumps by Abiomed, a Johnson & Johnson ( JNJ ) company, as the

most serious and said that its use could cause serious injuries

or death.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Anil

D'Silva)

Previous page： CMS to rework quality ratings for Medicare Advantage plans Next page： Hurco Temporarily Suspends Quarterly Dividend -- Shares Tumble Pre-Bell

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

CMS to rework quality ratings for Medicare Advantage plans

Jun 14, 2024

June 14 (Reuters) - The Centers for Medicare & Medicaid Services will recalculate the quality ratings of Medicare Advantage plans for people aged 65 years and above, the agency said, which would likely increase the bonus payments for insurers. ...

Hurco Temporarily Suspends Quarterly Dividend -- Shares Tumble Pre-Bell

Jun 14, 2024

09:01 AM EDT, 06/14/2024 (MT Newswires) -- Hurco ( HURC ) said Friday that it is temporarily suspending its regular quarterly cash dividend on its common stock, effective immediately. The company said the move aims to enhance its financial flexibility and improve its ability to manage market volatility. Hurco ( HURC ) said it can not guarantee it will resume...

Why Bio-Path Stock Is Climbing Today

Jun 14, 2024

Bio-Path Holdings, Inc. ( BPTH ) shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia. The Details: Bio-Path ( BPTH ) said the data presented showed prexigebersen continues to be well-tolerated and demonstrated efficacy results in two reporting...

Mereo BioPharma Prices $50 Million Offering

Jun 14, 2024

09:02 AM EDT, 06/14/2024 (MT Newswires) -- Mereo BioPharma ( MREO ) said Friday it priced an underwritten offering of about 12.5 million American depositary shares at $3.99 apiece for gross proceeds of about $50 million. The company said the offering is expected to close around Monday and net proceeds would be used to fund its setrusumab program, including supply...